GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Trial Profile

GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2017

At a glance

  • Drugs AFM 13 (Primary)
  • Indications Hodgkin's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GHSG-AFM13
  • Sponsors Affimed Therapeutics
  • Most Recent Events

    • 17 May 2017 According to an Affimed Therapeutics media release, full data from thsi study is anticipated in 2019.
    • 30 Mar 2017 According to an Affimed Therapeutics media release, company expects to report data collected from specific patient subsets enrolled under the original study protocol.
    • 11 Jan 2017 According to an Affimed Therapeutics media release, recruitment under the new study design is anticipated in the first quarter of 2017 and an update on the study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top